Table 2. Primary and Secondary Efficacy Outcomes.
| Outcome | Varenicline group, No. (%) | Placebo group, No. (%) | OR (95% CI) | P value |
|---|---|---|---|---|
| CAR at weeks | ||||
| 9-12 | 47 (31.3) | 11 (7.3) | 5.77 (2.85-11.66) | <.001 |
| 9-24 | 36 (24.0) | 9 (6.0) | 4.95 (2.29-10.70) | <.001 |
| 9-52 | 28 (18.7) | 9 (5.3) | 4.07 (1.79-9.27) | <.001 |
| 7-d point prevalence, wk | ||||
| 12 | 60 (40.0) | 16 (11.0) | 7.67 (3.91-15.05) | <.001 |
| 24 | 43 (29.0) | 13 (8.3) | 4.44 (2.17-9.07) | <.001 |
| 52 | 35 (23.7) | 14 (9.5) | 3.27 (1.57-6.78) | <.001 |
Abbreviations: CAR, continuous abstinence rate; OR, odds ratio.